Harrow Acquires US & Canadian Commercial Rights To VEVYE (Cyclosporine Ophthalmic Solution) 0.1% From Novaliq; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Harrow Health, Inc. (HROW) has acquired the US and Canadian commercial rights to VEVYE, a Cyclosporine Ophthalmic Solution, from Novaliq. The terms of the deal were not disclosed. VEVYE was approved by the FDA on May 30, 2023.
July 18, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harrow Health's acquisition of the commercial rights to VEVYE could potentially increase its market share and revenues in the future.
Acquiring the commercial rights to a FDA-approved product like VEVYE could potentially increase Harrow Health's market share and revenues. However, the impact will depend on the successful commercialization of the product and the market response.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100